Virupaksha Organics Limited

Virupaksha Organics Limited IPO: GMP today, Price, Review, Detail

by

Virupaksha Organics Limited is an R&D-driven Indian pharmaceutical company engaged in the manufacturing of active pharmaceutical ingredients (APIs), key starting materials (KSMs) and intermediates, and also provides contract development & manufacturing services to global pharma companies.
Its products span multiple therapeutic areas and serve customers in over 100 countries, supported by six manufacturing units in Telangana and Karnataka.

It serves over 550 customers in more than 100 countries, including major multinational pharmaceutical companies.

Virupaksha Organics has filed DRHP with SEBI for IPO with an issue size of ₹ 740 crore consisting completely as Fresh Issue of ₹ 740 crore and no Offer for Sale (OFS).

Subscription date to apply for the IPO is yet to be announced. Price band for the IPO is also pending to be declared.

Check DRHP
Check IPO Allotment
Visit Official Website
Issue Size:₹ 740 Crore
Fresh Issue:₹ 740 Crore
Offer for Sale:₹ 00 Crore
Price Range:TBA
Lot Size:TBA

Virupaksha Organics Limited important data points

Revenue, PAT, EBITDA

YearFiscal 2025
Networth₹ 456.6 Cr
Revenue:₹ 811.7 Cr
EBITDA₹ 144.2 Cr
PAT₹ 78.7 Cr
EBITDA Margin:~17.77%
PAT Margin~9.70%
Face Value:Rs. 10 per Equity Share

IPO important dates

Open Date:TBA
Close Date:TBA
Anchor Investor BiddingTBA
Allotment Date:TBA
Refunds & Demat CreditTBA
Tentative Listing Date:TBA

Use of Proceeds

PurposeAmount
Borrowing payment~ ₹ 195 Cr
Capacity Expansion~ ₹ 360 Cr
Technology & Infrastructure~ ₹ 0 Cr
Subsidiary Investment~ ₹ 0 Cr
General Corporate PurposeBalance

Virupaksha Organics Limited Financial Data

202320242025
Revenue (₹ Cr)₹ 644.8₹ 766.0₹ 811.7
Profit (₹ Cr)₹ 43.1₹ 73.7₹ 78.7
Asset (₹ Cr)₹ 601.8₹ 696.7₹ 952.5
Net Worth (₹ Cr)₹ 209.7₹ 275.3₹ 456.6

Virupaksha Organics IPO Grey Market Premium

DateIPO PriceIPO GMPProfit per lot
25-Jan₹ –₹ –₹ –
24-Jan₹ –₹ –₹ –
23-Jan₹ –₹ –₹ –
22-Jan₹ –₹ –₹ –
21-Jan₹ –₹ –₹ –
Virupaksha Organics Limited

Virupaksha Organics Limited IPO Pros & Cons

Strengths:

  • Strong growth potential in API and pharmaceutical intermediates globally.
  • Consistent revenue growth and profitability in recent years.
  • Diversified product portfolio across multiple therapeutic areas.
  • Established customer base of 550+ clients in 100+ countries.
  • IPO proceeds aimed at capacity expansion and debt reduction.

Risks:

  • Highly regulated industry with potential compliance risks.
  • Dependence on specific therapeutic segments may affect demand.
  • Manufacturing involves safety, environmental, and operational risks.
  • Success relies on timely innovation and new product development.
  • IPO valuation and listing performance remain uncertain.

Virupaksha Organics Limited Promoters – Pre offer equity (Approx)

Vedavathi Gangavaram~17.25%
Gangavaram Sri Lakshmi~9.98%
G Sri Vidya~9.49%
Chandra Mouliswar Reddy Gangavaram~9.14%
Balasubba Reddy Mamilla~2.43%

Virupaksha Organics Limited Lot Size details

Application TypeLot SizeNo. of LotsNo. of SharesInvestment Amount
Retail(Min)–1–₹ –
Retail (Max)–13–₹ –
Small HNI (Min)–14–₹ –
Small HNI (Max)–66–₹ –
Big HNI (Min)–67–₹ –

Lead Managers / Registrars of Virupaksha Organics Limited 

Lead / Book Running Lead ManagersAxis Capital Limited, SBI Capital Markets Limited
Registrar (RTA)KFin Technologies Limited.

Founding Year of Virupaksha Organics Limited & Managing Director

Virupaksha Organics Limited was incorporated in the year 1997.

Mr. Chandra Mouliswar Reddy Gangavaram is the Managing Director of the company.

Virupaksha Organics Limited FAQ

  • It is an R&D‑driven Indian pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), key starting materials (KSMs) and intermediates, and offers contract development and manufacturing services globally.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

  • Virupaksha Organics is raising funds via IPO to fund capacity expansion at multiple manufacturing units, prepay borrowings and to accelerate growth.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

  • The issue size of the IPO is approx ₹ 740 crore. It will be listed on the BSE & NSE platform.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

  • Risks to invest in the IPO is it’s regulatory compliance challenges, demand fluctuations in core therapeutic segments, operational and quality control risks, and reliance on customer relationships.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

  • Potential upsides to invest in the IPO is it’s expanding global API demand, diversified product portfolio, strong international customer base, and enhanced production capacity post‑IPO.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

  • You can apply online through ASBA via net banking or UPI‑enabled IPO applications on broker platforms during the subscription window once announced.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

  • Expected listing date is not yet announced.

    facebookShare on Facebook

    TwitterPost on X

    FollowFollow us

    PinterestSave

For more amazing blogs click here (IPO Corner).

facebookShare on Facebook
TwitterPost on X
FollowFollow us
PinterestSave

Leave a comment

RSS
Follow by Email
Facebook
X (Twitter)
Pinterest
Instagram
Telegram
WhatsApp